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inflammation but inhibits local interleukin-10
expression in a mouse allergic rhinitis model
Shui-Bin Wang1,3, Yu-Qin Deng1, Jie Ren1, Bo-Kui Xiao1, Zheng Liu2*† and Ze-Zhang Tao1*†Abstract
Background: Interleukin-10 (IL-10) has an important anti-inflammatory and immunoregulatory function, and its
expression is negatively correlated with the development and severity of allergic rhinitis (AR). However, the in vivo
effects of exogenous IL-10 on AR have not been studied and the mechanisms underlying the effects of IL-10 have
not been fully understood. Here, we investigated the effects of intranasal administration of recombinant mouse
(rm) IL-10 on the expression of Th responses and local IL-10 in a mouse model of AR induced by ovalbumin.
Results: Administration of rmIL-10 during challenge significantly reduced the number of eosinophils and mast cells,
as well as Type 2 helper T (Th2) and Th17 cell related cytokine and transcription factor levels in the nasal mucosa
and nasal lavage fluid in AR mice. The rmIL-10 treatment significantly inhibited the number of IL-10-positive cells
and IL-10 mRNA expression in the nasal mucosa in AR mice.
Conclusion: Our results show that exogenous IL-10 administrated in challenge phase alleviates nasal allergic
inflammation in AR mice, most likely by inhibiting Th2 and Th17 responses. It can also inhibit local IL-10 levels in
the nasal mucosa. Our findings indicate that IL-10 may have the potential as an inhibitor of AR.
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Allergic rhinitis (AR) is one of the most prevalent airway
diseases worldwide, which exerts a heavy burden on pa-
tients due to its impact on physical, social and emotional
functioning, as well as the cost of treatment. Despite the
increasing worldwide prevalence of AR, treatments for
AR remain limited in effect [1]. Thus, it is greatly
important to develop novel therapies with higher efficacy
for AR patients.
AR is characterized by a disturbance of T-cell subsets
and an accumulation of eosinophils and mast cells. CD4+
T-cell subsets are central regulators of immune responses
and allergic inflammatory diseases. After encountering
specific antigen, they become activated, proliferate, and* Correspondence: zhengliuent@hotmail.com; zezhangtaoent@163.com
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reproduction in any medium, provided the ordifferentiate into specific Type 1 helper T (Th1), Th2,
Th17, or regulatory T (Treg) cells distinguished by cyto-
kine profile, surface phenotype, and specific transcription
factor expression. AR has long been considered as an aller-
gic response involving predominantly Th2 cells, with a
relative insufficiency of Th1 cells [2]. However, in recent
years, the classic paradigm of Th1/Th2 cell-mediated im-
munity has been evolved to include novel subsets of Th
cell, such as Th17 cells and Treg cells. Exaggerated Th17
and impaired Treg responses have been implicated in the
development of AR and have been associated with corti-
costeroid resistance [2-7]. These T-cell subsets regulate
inflammatory responses mainly by secreting specific cyto-
kines such as interferon-γ (IFN-γ), IL-5, IL-17, IL-10, and
transforming growth factor-β1 (TGF-β1), as well as other
non-specific cytokines such as tumor-necrosis factor-α
(TNF-α) [3-6,8,9].
IL-10 is a multifunctional cytokine secreted by a var-
iety of cells, including T cells, monocytes, macrophages,
dendritic cells, and endothelial cells. IL-10 has diverse
effects on most hemopoietic cells. Its crucial role is totd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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responses [10]. In the sensitization phase of allergic re-
sponses, IL-10 can down-regulate major histocompatibility
complex class II and costimulatory molecule expression
on dendritic cells and induce anergic immune responses
possibly through up-regulating cytotoxic T lymphocyte-
associated molecule-4 (CTLA)-4 expression. In the effector
phase, IL-10 directly inhibits active CD4+ T cells prolifera-
tion and their function by crosslinking IL-10R on the sur-
face of activated CD4+ T cells, which engages the Jak family
signalling pathway of tyrosine kinases Jak1 and Tyk2 [11].
Because of its inhibitory properties, IL-10 has been sug-
gested as a potential therapy for systemic and localized
autoimmune and allergic inflammatory diseases, including
inflammatory bowel disease, allergic asthma, rheumatoid
arthritis, and experimental autoimmune encephalomyelitis
[10,12,13]. It has been reported that endogenous IL-10
levels in the nasal endothelium are decreased and nega-
tively correlated with AR development and severity in
AR patients [14,15], which makes us hypothesize that
IL-10 may alleviate allergic inflammation in AR. Here,
we investigated the effect of intranasal exogenous IL-10Figure 1 rmIL-10 reduced the infiltration of eosinophils and mast cell
magnification × 400) of nasal mucosa sections of mice stained with haema
staining for mast cells (white arrows) (A). A significantly increased number
observed in the AR group compared with the control group, and such incr
Control group, saline-sensitized and challenged mice; AR group, ovalbumin
with rmIL-10 during challenge.administration on the allergic inflammation of AR in a
mouse model induced by ovalbumin (OVA).
Results
rmIL-10 reduces the number of eosinophils and mast cells
in nasal mucosa in AR mice
To determine the in vivo effects of rmIL-10 on AR, an
OVA-induced mouse AR model was used. The IL-10
group received 0.1 μg/mouse of rmIL-10 simultaneously
with OVA challenge. The control group received PBS
sensitization and challenge instead of OVA. Mice were
sacrificed and nasal mucosa inflammation was evaluated
at 24 hours after the final challenge (day 28). The infil-
tration of eosinophils and mast cells was mainly found
in the lamina propria (LP) of nasal mucosa. The cyto-
plasm was stained red for eosinophils with H&E stain-
ing, while the cytoplasm was stained purple for mast
cells with mast cell staining (Figure 1A). The number of
eosinophils and mast cells was significantly increased in
AR group compared with that seen in the control group
(p < 0.05), and this increase was markedly inhibited by
rmIL-10 treatment (p < 0.05) (Figure 1B and C).s in nasal mucosa. Representative photomicrographs (original
toxylin and eosin (H&E) for eosinophils (black arrows) or by mast cell
of eosinophils (B) and mast cells (C) in the lamina propria (LP) were
ease was obviously alleviated by rmIL-10 treatment in the IL-10 group.
-sensitized and challenged mice; IL-10 group, AR mice were treated
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levels but decreases other cytokine levels in nasal lavage
fluid
To determine the effects of rmIL-10 on the Th cell
related cytokine levels in the nasal cavity, the protein levels
of IFN-γ, IL-5, IL-17, IL-10, and TGF-β1 in the nasal
lavage fluid (NLF) were analyzed by ELISA. Compared
with those seen in the control group, the levels of IFN-γ,
IL-5, IL-17, and TGF-β1 in NLF were significantly in-
creased in the AR group (p < 0.05), and such up-regulation
was markedly inhibited by rmIL-10 treatment (p < 0.05)
(Figure 2A, B, D, and E). The levels of IL-10 in NLF
were also significantly increased in AR group in compari-
son with those seen in the control group (p < 0.05), but
was further increased with rmIL-10 treatment (p < 0.05)
(Figure 2C).
rmIL-10 differentially modulates mRNA expression of Th
cell related cytokines and T-cell subset transcription
factors in nasal mucosa
To further determine the effects of rmIL-10 on allergic
airway inflammation, we used qPCR to examine the
mRNA expression of Th cell related cytokines and T-cell
subset transcription factors in the nasal mucosa. Signifi-
cantly up-regulation of mRNA expression levels of IL-5,
IL-17, IL-10, TGF-β1, and TNF-α were found in the AR
group compared with that seen in the control group
(p < 0.05), and this up-regulation was markedly decreasedFigure 2 rmIL-10 administration increased total IL-10 levels but decre
fluid (NLF) were assessed by means of ELISA. Compared with the control g
in AR group, and rmIL-10 administration during challenge markedly reduce
increased the IL-10 levels (C). Control group, saline-sensitized and challeng
group, AR mice were treated with rmIL-10.after treatment with IL-10 in the IL-10 group (p < 0.05)
(Figure 3C, E, G, H, J). IFN-γ mRNA expression levels
were comparable between the control and AR groups,
whereas it was slightly decreased in the IL-10 group
compared with the AR group (p < 0.05), (Figure 3A).
The mRNA expression levels of GATA-3 and ROR-c
(Figure 3D, F) were significantly higher in the AR group
than in the control group and significantly lower in the IL-
10 group than in the AR group (p < 0.05). Foxp3 mRNA
expression levels were slightly increased in the AR group
compared with those seen in the control group (p < 0.05),
whereas rmIL-10 had no significant effect on its expression
(Figure 3I). T-bet mRNA expression levels were compar-
able across different study groups (Figure 3B).
rmIL-10 reduced local IL-10–positive cells in nasal mucosa
The protein expression and cellular location of IL-10
in the nasal mucosa were investigated using immuno-
histochemistry. IL-10 immunoreactivity was found in
epithelial cells and infiltrating inflammatory cells in LP
(Figure 4A-D). No immunoreactivity was observed in
nasal mucosa stained with the negative control (isotype
rabbit IgG) for anti-IL-10 (Figure 4E). The number of
IL-10-positive cells in the nasal mucosa was significantly
increased in the AR group compared with that seen in
the control group (p < 0.05), and such increase was
markedly suppressed with IL-10 treatment in the IL-10
group (p < 0.05), (Figure 4F).ased other cytokine levels in NLF. Cytokine levels in nasal lavage
roup, the levels of all cytokines in the NLF were significantly elevated
d the levels of IFN-γ, IL-5, IL-17, and TGF-β1 (A-B and D-E), but further
ed mice; AR group, ovalbumin-sensitized and challenged mice; IL-10
Figure 3 rmIL-10 differentially modulated mRNA expression of Th subsets related cytokines and transcription factors in nasal mucosa.
The mRNA relative expression levels of IL-5, IL-17, IL-10, TGF-β1, and TNF-α (C, E, G, H, and J) were significantly up-regulated in the AR group
compared with the control group, and such up-regulation was markedly inhibited in AR mice with rmIL-10 treatment during challenge. Com-
pared with the control group, IFN-γ mRNA expression levels (A) moderately increased without statistical significance,, but were significantly
down-regulated with rmIL-10 treatment in AR mice. Compare with the control group, AR mice demonstrated significantly up-regulated the mRNA
expression levels of GATA-3 and ROR-c in the nasal mucosa that were markedly suppressed with rmIL-10 treatment (D and F). Although AR mice
had moderately increased Foxp3 mRNA expression levels compared with controls, but rmIL-10 treatment had no effect on Foxp3 mRNA expres-
sion (I). There was no significant difference for T-bet mRNA expression levels among different groups (B). T-bet, T-box transcription factor; GATA-
3, GATA binding protein 3; ROR-c, retinoic acid-related orphan receptor C; Foxp3, Forkhead box P3. Control group, saline-sensitized and chal-
lenged mice; AR group, ovalbumin-sensitized and challenged mice; IL-10 group, AR mice were treated with rmIL-10 during challenge.
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In this study, we demonstrated that rmIL-10 administra-
tion during challenge could alleviate allergic inflamma-
tory response in AR mice, which was evidenced by the
decreased infiltration of eosinophils and mast cells, and
reduced Th2 and Th17 responses. In contrast, interest-
ingly, rmIL-10 inhibited the local IL-10 expression in the
nasal mucosa.
AR is characterized by the accumulation of eosinophils
and mast cells. Th cells and their secreted cytokines playa central role in regulating the migration, apoptosis, and
function of eosinophils and mast cells in AR. Th2
cells secrete IL- 4, IL-5, IL-10, and IL-13, which mount
humoral immunity by inducing IgE production by B
cells and by activating mast cells and eosinophils, while
Th1 cells mediate cellular immunity by secreting IFN-γ.
It has been considered that the function of Th1 and Th2
cells is inhibited by each other [2]. In line with a pre-
vious finding, we found that T-bet expression was not
significantly changed in AR mice compared with the
Figure 4 rmIL-10 reduced local IL-10 expression in nasal mucosa. IL-10 immunohistochemistry for IL-10-positive cells in the nasal mucosa of
mice was carried out by using the streptavidin-biotin complex method. Representative photomicrographs (original magnification × 400) of IL-10
immunohistochemical staining of nasal mucosa sections from the control mice (A), AR mice (B), and AR mice treated with rmIL-10 (C), and
sections stained with negative control for anti-IL-10 antibody (E). A representative photomicrograph with enlarged magnification (original
magnification × 1000) of IL-10 immunohistochemical staining of nasal mucosa sections from AR mice (D). The number of IL-10-positive cells was
significantly higher in the AR group compared with the control group, and it was reduced in the AR group compared with the IL-10 group (F).
Control group, saline-sensitized and challenged mice; AR group, OVA-sensitized and challenged mice; IL-10 group, AR mice were treated with
rmIL-10 during challenge.
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NLF and nasal mucosa were slightly increased in AR mice
compared with the controls, and were down-regulated
with rmIL-10 treatment during challenge. The inconsist-
ent expression between IFN-γ and T-bet was not very sur-
prising. It has been reported that IFN-γ is secreted by a
variety of cells, including Th1 cells, macrophages, and epi-
thelial cells, but T-bet is only expressed by Th1 cells. We
also showed that Th2 responses (IL-5, IL-10, and GATA-3
expression) were markedly down-regulated with rmIL-10
treatment, suggesting that IL-10 can suppress Th2 reac-
tions [12,13].
IL-17-producing Th17 cells, induced in vitro by IL-6,
IL-23, and TGF-β1, and regulated by transcription factor
ROR-c, have multiple functions in different inflamma-
tory airway diseases. Th17 cells have not only been indi-
cated in control of the mucosal pathogen, but also are
involved in the pathogenesis of Th1-mediated inflamma-
tory diseases [3,4]. Recently, Th17 cells have been associ-
ated with Th2 predominated allergic diseases. Increased
expression of Th17 responses has been found in asthma,
AR, and nasal polyps [5,17-19]. Th17 cells have been
demonstrated to promote the development and augment
the severity of allergic inflammatory airway diseases by
secreting pro-inflammatory cytokines and chemokines,
such as IL-1β, IL-6, IL-8, and IL-17 [5,17,18]. Interestingly,
increased IL-17 expression is associated with resistance tocorticosteroid in AR patients [20]. Consistent with previ-
ous reports [5,7], we showed that the expression levels of
IL-17, ROR-c, and TGF-β1 were significantly increased in
AR mice compared with the control mice. Moreover, we
found that the increased expression of Th17 responses
could be significantly down-regulated by IL-10 treatment
in AR mice. A probable underlying mechanism may be
that IL-10 combines IL-10R on the surface of activated
Th17 cells and inhibits proliferation and function of Th17
cells [11]. It has also been reported that an intermediate
subset of T cells, Foxp3+ IL-17+ T cells, exist in the nasal
mucosa of patients with AR, which can be converted to
Foxp3+ Treg under the influence of IL-10 [21]. In this
study, we found an inhibition of ROR-c expression with-
out an increase of Foxp3+ expression. Therefore, we could
not preclude the possibility that rmIL-10 may down-
regulate Th17 responses by promoting the conversion of
Foxp3+ IL-17+ T cells to Foxp3+ Treg [21]. However, this
needs further investigation in future.
Unlike other effector CD4+ T cells, Treg cells have
been implicated in peripheral tolerance as an inhibitor
of immune responses. Treg cells are classified into nat-
ural Treg (nTreg) generated in the thymus and induced
Treg (iTreg) cells induced by IL-10 or TGF-β1 in the
periphery. Both of them are required for the full expres-
sion of tolerance but have a division of labour in im-
mune homeostasis. nTreg cells migrate preferentially to
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immune disease, and can be recruited and activated
early during an immune response to control its magni-
tude, whereas iTreg cells are induced upon repeated
antigen stimulation, act later to reduce the activation
of T cells directed against environmental antigens and
to restore and maintain tolerance [22-25]. One of the
iTreg cells is Type 1 Regulatory T (Tr1) cells that are
induced by IL-10. A few studies have demonstrated
that iTreg cells also express Foxp3 upon activation.
However, Foxp3 expression on Tr1 cells is low and
transient or never reaches the high expression levels
that characterize Foxp3+ Treg. Furthermore, Foxp3 is
not required for Tr1 cell induction or function since
suppressive Tr1 cells can be generated or isolated from
peripheral blood of patients with Foxp3-mutations,
even in those patients with complete deletion of Foxp3
[26,27]. Therefore, Tr1 cells may not express Foxp3
and their immunosuppressive effects are partly inhib-
ited by anti-IL-10 neutralizing antibody [27]. Tr1 cells,
but not nTreg cells, were decreased in the peripheral
blood of patients with AR [25,28]. In the present study,
total Foxp3 mRNA expression was slightly increased in
AR mice compared with the controls, reflecting a pos-
sible increased recruitment of nTreg to nasal mucosa
or activation of T cells in nasal mucosa. IL-10 treat-
ment may induce accumulation of Tr1 in nasal mu-
cosa, however, the limited amount of murine nasal
mucosa does not allow the flow cytometric analysis of
Tr1 in nasal mucosa based on the co-expression of
CD49b and lymphocyte activation gene 3 on Tr1 [26].
We found that IL-10 protein levels in NLF, and IL-10
mRNA expression level and IL-10-positive cell number in
the nasal mucosa were significantly increased in AR mice
compared with the control mice. Immunohistochemistry
showed that IL-10-immunoreactivity was mainly in epi-
thelial cells and inflammatory cells in LP. Previous studies
have demonstrated that IL-10-positive cells are mainly T
and B lymphocytes, monocytes, macrophages, and mast
cells in LP in allergic responses [10,29]. In this study,
we found that rmIL-10 treatment further increased IL-
10 protein levels in NLF. In order to determine if in-
creased IL-10 protein levels in NLF came from the
exogenous rmIL-10 or induced local IL-10 expression in
nasal mucosa, we investigated the IL-10 mRNA and pro-
tein expression in the nasal mucosa and found that IL-10
expression in nasal mucosa was markedly decreased with
rmIL-10 treatment. The results indicate that exogenous
IL-10 treatment can inhibit the local IL-10 expression in
the nasal mucosa and the increased IL-10 protein levels in
NLF are derived from exogenous rmIL-10.
In the study, local treatment with rmIL-10 significantly
alleviated Th2 and Th17 responses in the nasal mucosa.
The increased expression of IL-17 has been shown to benegatively associated with the sensitivity of AR patients
to topical corticosteroid treatment [20]. IL-10 can upreg-
ulate glucocorticoid-receptor expression of asthmatic
CD4+ T cells with glucocorticoid-resistant [29]. Thus,
IL-10 may have potential benefits for the treatment of
AR patients with corticosteroid resistance. It is well
accepted that Th1 and Treg cells play an important role in
constraining allergic reactions. Their under-expression or
dysfunction is closely related to the development of AR.
Our study suggests that IL-10 administration at current
dose may not cause significant suppression to the immun-
ity against allergic airway responses since it had not appar-
ently inhibitory effect on the expression of Th1 and Treg
cells.
Although glucocorticoids have been used for the treat-
ment of inflammatory and allergic airway diseases for a
long time, their side effects have been concerned for
many years, such as growth inhibition, osteoporosis, and
gastric ulcer [30-32]. Based on its anti-inflammation
function, intranasally delivered IL-10 has the potential to
be an alternative drug for glucocorticoids and therefore
to avoid side effects of glucocorticoids.
Our current study has several limitations. One is that
given the limited amount of mouse nasal tissues, we could
not perform the flow cytometric analysis of Th subsets at
cellular level. Second, our AR mouse model was estab-
lished by OVA sensitization and challenge. It may be bet-
ter to induce AR with relevant allergens found in human
AR, such as pollens and dust mites. Third, we adminis-
trated exogenous IL-10 during challenge instead of after
the establishment of AR. Therefore, the therapeutic effect
of IL-10 on established AR needs to be studied in the
future research.
Conclusions
In conclusion, the study demonstrates that rmIL-10
administration during challenge down-regulates allergic
reactions in the context of AR, most likely through inhi-
biting Th2 and Th17 responses without impairment of
Th1 and Treg responses. Exogenous IL-10 can also in-
hibit local IL-10 expression in the nasal mucosa in the
context of AR. Given its anti-inflammatory and im-
munosuppressive functions, IL-10 may have a promising




C57BL/6 J mice (6–8 weeks old) were purchased from
the Shanghai Experimental Animal Center (Shanghai,
China). These animals were kept in a special pathogen-free
biohazard containment facility and were used following
protocols approved by the Animal Care and Use Commit-
tee of Renmin Hospital of Wuhan University.
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administration
A total of 48 mice were randomly divided into the con-
trol, AR, and IL-10 groups with 8 mice in each group,
and 2 independent experiments were performed. OVA
(Grade V, Sigma, St. Louis, MO) was used for allergen
sensitization and challenge to establish the AR mouse
model according to the method previously described
[16]. Briefly, on days 0, 7, and 14, mice were immunized
by intraperitoneal injection of 25 μg OVA and 1 mg alu-
minium hydroxide in 300 μl phosphate-buffered saline
(PBS), and followed by daily intranasal challenge (from
day 21 to 27) with 2.5% OVA in 40 μl PBS (20 μl for each
nose). The control group received PBS sensitization and
challenge instead of OVA. The IL-I0 group received 0.1 μg
rmIL-10 (PeproTech, USA) administration simultaneously
with OVA challenge continuously for 7 days [12].
Nasal lavage
Four mice per group were underwent nasal lavage before
histopathology. Nasal lavage was carried out using the
method previously described with slight modifications
[33]. The nasal cavity was gently irrigated with l ml of
sterile saline, and the nasal lavage fluid (NLF) was col-
lected and centrifuged. The supernatants were stored at
−20°C for cytokine measurement using enzyme-linked
immunosorbent assay (ELISA).
Measurement of cytokines in NLF
The levels of IL-5, IL-10, IL-17, TGF-β1, and IFN- γ in
NLF were measured by means of ELISA. The ELISA kits
were all from Boster Biotech (Wuhan, China) and their
detection sensitivity was 2 pg/ml for all the cytokines.
All the procedures were performed according to the
manufacturer’s instructions.
Histopathology
Four mice per group were underwent histopathology.
Sections were prepared as described elsewhere [34].
Histological changes in the nasal mucosa were examined
through haematoxylin and eosin (HE) staining for eosin-
ophils and mast cell staining for mast cells. Eosinophils
and mast cells in the LP were counted in 4 randomly
selected fields. The results for eosinophils and mast cells
were expressed as numbers /mm2 and numbers per
high-power (HP) field, respectively.
RNA extraction and quantitative real-time RT-PCR
Four mice were selected from each group and the nasal
mucosa were obtained and homogenized as described else-
where [34]. Total RNA was extracted by Trizol (Invitrogen,
Carlsbad, CA, USA) and 0.5 μg of total RNA was used
for the reverse-transcription reaction using a Rever Tra
Ace qPCR RT Kit (TOYOBO, Japan) according to themanufacturer’s instructions. The qPCR was carried out
for the detection of mRNA expression of T-bet (NM_
019507.2), GATA-3 (NM_008091.3), ROR-c (NM_011
281.2), Foxp3 (NM_001199348.1), IFN-γ (NM_00833
7.3), IL-5 (NM_010558.1), IL-17 (NM_010552.3), IL-10
(NM_010548.2), TGF-β1 (NM_011577.1), and TNF-α
(NM_013693.2). The reaction was performed with an
ABI 7500 Real-time PCR system (Applied Biosystems,
USA) using the SYBR qPCR Mix (TOYOBO, Japan)
according to the manufacturer’s protocol. An analysis
of relative expression was calculated using the 2-ΔΔCT
method as described elsewhere, and one sample from a
control served as a calibrator [35]. Glyceraldehyde-3-
phosphate dehydrogenase (GAPDH, NM_008084.2) was
used as a housekeeping gene for normalization, and a
no-template sample was used as a negative control.
Immunohistochemistry
Rabbit anti-mouse polyclonal anti-IL-10 antibody (Boster
Biotech, Wuhan, China) was diluted by 1:100. The im-
munoreactivity was detected using a Streptavidin-Biotin
Complex (SABC) Kit (Boster Biotech, Wuhan, China)
and 3, 3′-diaminobenzidine tetrahydrochloride, which
rendered positive cells brown. Control isotype rabbit
IgG was used as a negative control [35]. The number of
IL-10-positive cells per high-power field of epithelium
and LP was counted.
Statistical analysis
All results are expressed as the means ± SEM. Results
from the different groups were compared using the
non-parametric Kruskal-Wallis test, and followed by the
Mann–Whitney U test. Statistical analysis was performed
using IBM SPSS Statistics 19.0 software (IBM, USA), and
p < 0.05 was considered statistically significant.
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